In addition, semaglutide had the greatest risk of nausea, diarrhea, vomiting, constipation, and pancreatitis, while liraglutide had the greatest risk of upper abdominal pain
Treatment response : As per NICE guidance, assess response after 6 months and continue only if adequate benefit is demonstrated (HbA1c reduction of at least 11 mmol/mol [1%] and/or 3% weight loss from initial body weight)
Chin J Nat Med 2020;18:80317
Early research indicates oral semaglutide (rybelsus) achieves meaningful weight loss when dosed appropriately, though absorption varies with food intake and individual gastrointestinal factors
Tadalafil Description 7-9 Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, has a mean terminal half-life of over 17 hours